Sr. Manager/Associate Director, Training – Medical Affairs at Corcept Therapeutics

Remote

Apply with AI Apply

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Pharmaceuticals, HealthcareIndustries

Requirements

Candidates must possess a strong scientific background, proven experience in training development and facilitation, and a passion for operational excellence in a fast-paced, collaborative environment. A strong knowledge of the pharmaceutical industry and medical affairs field dynamics is required, along with excellent communication, facilitation, coaching, and project management skills. High attention to detail and a proactive, team-oriented mindset are essential. Experience in endocrinology or cardiometabolism is preferred, as is proficiency in Microsoft Office, LMS tools, and virtual platforms.

Responsibilities

The Sr. Manager/Associate Director of Training will collaborate with the Director of Training to design, implement, and evaluate training programs for Medical Science Liaisons and other medical affairs professionals. Responsibilities include co-facilitating new hire onboarding, developing and delivering ongoing education initiatives, curating scientific content, and monitoring performance trends to identify learning needs. The role also involves contributing to team meetings, leading training sessions, creating and maintaining a structured training curriculum, designing assessment tools, and collaborating cross-functionally with various stakeholders. Additionally, the position may require temporary territory coverage for MSLs and managing training initiative logistics, timelines, and vendor deliverables.

Skills

Training Development

Training Facilitation

Medical Affairs

Onboarding Programs

Scientific Content

Cross-functional Collaboration

Legal

Compliance

Clinical

Endocrinology

Oncology

Neurology

Medical Science Liaisons (MSLs)

Corcept Therapeutics

Develops cortisol modulators for medical conditions

About Corcept Therapeutics

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing various health issues. Their main product, Korlym, is used to treat Cushing's syndrome, a condition caused by too much cortisol. Korlym was approved by the FDA in 2012 and is the first medication specifically for this disorder. Corcept stands out from competitors by having a strong emphasis on research and development, having discovered over 1,000 unique cortisol modulators. The company aims to expand its range of treatments while also providing educational resources to healthcare professionals and patients to improve understanding and care for cortisol-related conditions.

Menlo Park, CaliforniaHeadquarters

1998Year Founded

$39.7MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Remote Work Options

Flexible Work Hours

Risks

Teva's antitrust lawsuit could lead to legal expenses and market share loss.

Heavy reliance on Korlym makes Corcept vulnerable to market fluctuations.

Recent investments may pressure Corcept for short-term financial performance, impacting R&D.

Differentiation

Corcept specializes in cortisol modulation, a niche with few direct competitors.

Korlym is the first FDA-approved treatment for Cushing's syndrome, a significant market advantage.

Corcept's extensive R&D has led to the discovery of over 1,000 selective cortisol modulators.

Upsides

Increased interest in cortisol therapies for mental health boosts Corcept's R&D prospects.

Advancements in drug delivery systems could enhance Corcept's product efficacy.

The FDA's fast-track designation supports Corcept's innovative cortisol-related treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free